Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosibelimab in Relapsed/Refractory Lymphoma
NCT03778073Phase 1Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Apr 2019
- Primary completion
- May 2022
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of cosibelimab-ipdl in B-cell non-Hodgkin lymphoma and Richter syndrome (RS) (3 arms), sponsored by TG Therapeutics, Inc. Primary endpoint: Adverse Events That Are Related to Treatment at 6 months. Started Apr 2019; status: terminated.
02
Drugs
cosibelimab-ipdl
03
Conditions
B-cell non-Hodgkin lymphomaRichter syndrome (RS)
Beyond the preview
Go deeper on NCT03778073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778073.